About Zentalis

We are focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer. Using our industry expertise, we have developed an integrated approach to identify and overcome the limitations of current cancer therapeutics, enabling us to design better small molecules for improved patient outcomes.

Learn More

Pipeline

Drug NameDrug
DiseaseDis
IND EnablingIND
Phase 1/2Ph 1/2
Phase 3Ph 3
CollaboratorCollab
Breast Cancer
Breast Cancer
Pfizer
ZN-c3: WEE1
Solid Tumors
ZN-c3: WEE1
Solid Tumors
Zentera
ZN-d5: BCL-2
Hematologic Malignancies
ZN-d5: BCL-2
Hematologic Malignancies
Zentera
ZN-e4: EGFR
NSCLC
ZN-e4: EGFR
NSCLC

Learn More

Join Zentalis

Learn More